1206 related articles for article (PubMed ID: 16487836)
1. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
4. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
6. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
7. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
9. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
10. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
11. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
12. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
13. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
14. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
[TBL] [Abstract][Full Text] [Related]
15. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Maggioni AP; Fabbri G
Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
[TBL] [Abstract][Full Text] [Related]
16. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Reed SD; McMurray JJ; Velazquez EJ; Schulman KA; Califf RM; Kober L; Maggioni AP; Van de Werf F; White HD; Diaz R; Mareev V; Murin J;
Am Heart J; 2006 Sep; 152(3):500-8. PubMed ID: 16923421
[TBL] [Abstract][Full Text] [Related]
17. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
[TBL] [Abstract][Full Text] [Related]
18. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
20. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Pfeffer MA
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S41-3. PubMed ID: 17199221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
